RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES
Background Glioblastoma (GBM) is one of the most aggressive brain cancers, with a median overall survival (OS) of about 15 months. This retrospective study focuses on 144 GBM cases treated over 12 years in our clinic in Romania, analyzing factors affecting progression-free survival (PFS) and OS,...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
London Academic Publishing
2024-11-01
|
| Series: | Romanian Neurosurgery |
| Subjects: | |
| Online Access: | http://journals.lapub.co.uk/index.php/roneurosurgery/article/view/2817 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846167630298218496 |
|---|---|
| author | Alexandru Vlad Ciurea Razvan Onciul Razvan-Adrian Covache-Busuioc Luca-Andrei Glavan Corneliu Toader |
| author_facet | Alexandru Vlad Ciurea Razvan Onciul Razvan-Adrian Covache-Busuioc Luca-Andrei Glavan Corneliu Toader |
| author_sort | Alexandru Vlad Ciurea |
| collection | DOAJ |
| description |
Background
Glioblastoma (GBM) is one of the most aggressive brain cancers, with a median overall survival (OS) of about 15 months. This retrospective study focuses on 144 GBM cases treated over 12 years in our clinic in Romania, analyzing factors affecting progression-free survival (PFS) and OS, including genetic markers and treatment modalities.
Methods
This study involved patients treated between 2012 and 2024 at the National Institute of Neurology and Neurovascular Diseases in Bucharest. The cohort included 144 patients, with variables such as age, gender, tumor location, IDH mutation status, Karnofsky Performance Status (KPS), and genetic markers (MGMT methylation and EGFR amplification) analyzed. Survival outcomes were evaluated using Kaplan-Meier curves and log-rank tests.
Results
- Patient Demographics: The cohort included 64 males (44.4%) and 80 females (55.6%) with a mean age of 60.7 years.
- Tumor Characteristics: The most common tumor location was the frontal lobe (31.9%), followed by multilobular GBM (26.3%). Right-side tumors were more prevalent (51.3%).
- Genetic Markers: MGMT promoter was methylated in 46 patients (31.9%), and EGFR was amplified in 76 patients (52.7%).
- Treatment Modalities: 105 patients (72.9%) received chemotherapy with temozolomide (TMZ), and 116 patients (80.5%) underwent radiotherapy.
- Survival Outcomes: Median PFS was 5 months, and median OS was 8.5 months. Kaplan-Meier survival curves indicated significantly increased OS in patients with MGMT methylation undergoing chemotherapy (p<0.005) and radiotherapy (p<0.005). Similarly, OS was significantly higher in patients without EGFR amplification receiving chemotherapy (p<0.005) and radiotherapy (p<0.005).
Conclusion
The study emphasizes the importance of MGMT methylation and EGFR amplification in predicting survival outcomes in GBM patients. Immediate postoperative adjuvant therapy significantly improves PFS and OS. The findings underscore the need for coordinated care and timely access to adjuvant therapies to enhance survival rates in GBM patients. Second surgical interventions also showed a survival benefit, highlighting their potential role as salvage therapy in recurrent GBM cases.
|
| format | Article |
| id | doaj-art-c2efe6a12ca3456ca95f851ea701dfd3 |
| institution | Kabale University |
| issn | 1220-8841 2344-4959 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | London Academic Publishing |
| record_format | Article |
| series | Romanian Neurosurgery |
| spelling | doaj-art-c2efe6a12ca3456ca95f851ea701dfd32024-11-14T15:47:10ZengLondon Academic PublishingRomanian Neurosurgery1220-88412344-49592024-11-0138Special Issue10.33962/roneuro-2024-093RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMESAlexandru Vlad CiureaRazvan OnciulRazvan-Adrian Covache-BusuiocLuca-Andrei GlavanCorneliu Toader Background Glioblastoma (GBM) is one of the most aggressive brain cancers, with a median overall survival (OS) of about 15 months. This retrospective study focuses on 144 GBM cases treated over 12 years in our clinic in Romania, analyzing factors affecting progression-free survival (PFS) and OS, including genetic markers and treatment modalities. Methods This study involved patients treated between 2012 and 2024 at the National Institute of Neurology and Neurovascular Diseases in Bucharest. The cohort included 144 patients, with variables such as age, gender, tumor location, IDH mutation status, Karnofsky Performance Status (KPS), and genetic markers (MGMT methylation and EGFR amplification) analyzed. Survival outcomes were evaluated using Kaplan-Meier curves and log-rank tests. Results - Patient Demographics: The cohort included 64 males (44.4%) and 80 females (55.6%) with a mean age of 60.7 years. - Tumor Characteristics: The most common tumor location was the frontal lobe (31.9%), followed by multilobular GBM (26.3%). Right-side tumors were more prevalent (51.3%). - Genetic Markers: MGMT promoter was methylated in 46 patients (31.9%), and EGFR was amplified in 76 patients (52.7%). - Treatment Modalities: 105 patients (72.9%) received chemotherapy with temozolomide (TMZ), and 116 patients (80.5%) underwent radiotherapy. - Survival Outcomes: Median PFS was 5 months, and median OS was 8.5 months. Kaplan-Meier survival curves indicated significantly increased OS in patients with MGMT methylation undergoing chemotherapy (p<0.005) and radiotherapy (p<0.005). Similarly, OS was significantly higher in patients without EGFR amplification receiving chemotherapy (p<0.005) and radiotherapy (p<0.005). Conclusion The study emphasizes the importance of MGMT methylation and EGFR amplification in predicting survival outcomes in GBM patients. Immediate postoperative adjuvant therapy significantly improves PFS and OS. The findings underscore the need for coordinated care and timely access to adjuvant therapies to enhance survival rates in GBM patients. Second surgical interventions also showed a survival benefit, highlighting their potential role as salvage therapy in recurrent GBM cases. http://journals.lapub.co.uk/index.php/roneurosurgery/article/view/2817glioblastomaoverall survivalKaplan-Meier survival curveslog-rank tests |
| spellingShingle | Alexandru Vlad Ciurea Razvan Onciul Razvan-Adrian Covache-Busuioc Luca-Andrei Glavan Corneliu Toader RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES Romanian Neurosurgery glioblastoma overall survival Kaplan-Meier survival curves log-rank tests |
| title | RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES |
| title_full | RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES |
| title_fullStr | RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES |
| title_full_unstemmed | RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES |
| title_short | RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA OUTCOMES |
| title_sort | retrospective analysis of glioblastoma outcomes |
| topic | glioblastoma overall survival Kaplan-Meier survival curves log-rank tests |
| url | http://journals.lapub.co.uk/index.php/roneurosurgery/article/view/2817 |
| work_keys_str_mv | AT alexandruvladciurea retrospectiveanalysisofglioblastomaoutcomes AT razvanonciul retrospectiveanalysisofglioblastomaoutcomes AT razvanadriancovachebusuioc retrospectiveanalysisofglioblastomaoutcomes AT lucaandreiglavan retrospectiveanalysisofglioblastomaoutcomes AT corneliutoader retrospectiveanalysisofglioblastomaoutcomes |